ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Boeing Acquisition of Spirit AeroSystems Could Close Soon Amid Ongoing Conditions 
Visa to Move European Headquarters to London’s Canary Wharf 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Waymo Issues Recall After Reports of Self-Driving Cars Illegally Passing School Buses in Texas 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans, impacting overall financial performance.
A company spokesperson stated, “We did not meet our financial goals in 2024, and that’s reflected in our corporate bonus.”
CVS experienced a surge in Medicare enrollments, leading to increased expenses. The company also struggled with higher medical service utilization, a shift in quality ratings, and elevated costs from sicker Medicaid members. These factors contributed to financial setbacks, prompting executive changes and restructuring efforts.
In October, CVS replaced CEO Karen Lynch with longtime company executive David Joyner following investor pressure, including from activist Glenview Capital. Joyner has since initiated cost-cutting measures and appointed a new insurance head to stabilize operations.
Despite financial challenges, CVS recently exceeded Wall Street’s fourth-quarter profit expectations and provided an annual forecast aligning with analyst estimates. This signals potential improvement under the new leadership.
As CVS navigates economic headwinds, its strategic adjustments will be crucial in restoring growth and shareholder confidence.
